Corvus Pharmaceuticals reported a net loss of $8.0 million for Q2 2025, an increase from $4.3 million in Q2 2024, primarily due to higher research and development expenses. The company's cash position significantly improved to $74.4 million, bolstered by $35.7 million from warrant exercises, extending its cash runway into Q4 2026. Key clinical advancements include positive Phase 1 data for soquelitinib in atopic dermatitis and ongoing enrollment in Phase 3 PTCL and Phase 2 ALPS trials.

Corvus Pharmaceuticals reported a net income of $15.2 million for the first quarter of 2025, a significant improvement compared to a net loss in the prior year, primarily driven by a substantial gain from the change in the fair value of the warrant liability. The company also provided positive updates on its clinical pipeline, particularly for soquelitinib in atopic dermatitis and peripheral T cell lymphoma, and reported additional cash from warrant exercises.

Corvus Pharmaceuticals posted a net loss of $12.1 million in Q4 2024, driven by higher R&D spending and changes in warrant liabilities. The company ended the quarter with $52 million in cash, funding operations into Q1 2026, while continuing to progress key clinical programs.

Corvus Pharmaceuticals reported a net loss of $40.2 million for the third quarter ended September 30, 2024, compared to a net loss of $6.0 million for the same period in 2023. As of September 30, 2024, Corvus had cash, cash equivalents and marketable securities of $41.7 million compared to $27.1 million as of December 31, 2023. The company expects its cash to fund operations into 2026.

Corvus Pharmaceuticals reported a net loss of $4.3 million for the second quarter of 2024, and had cash, cash equivalents and marketable securities of $47.2 million as of June 30, 2024. The company expects its cash to fund operations into the fourth quarter of 2025.

Corvus Pharmaceuticals reported a net loss of $5.7 million for the first quarter ended March 31, 2024. The company's cash, cash equivalents, and marketable securities totaled $22.1 million as of March 31, 2024, which does not include the $30.6 million from a financing completed on May 6, 2024.

Corvus Pharmaceuticals reported a net loss of $6.7 million for the fourth quarter of 2023, compared to a net loss of $9.8 million for the same period in 2022. The company's cash, cash equivalents, and marketable securities totaled $27.1 million as of December 31, 2023.

Corvus Pharmaceuticals reported a net loss of $6.0 million for the third quarter ended September 30, 2023, compared to a net loss of $14.8 million for the same period in 2022. As of September 30, 2023, Corvus had cash, cash equivalents and marketable securities of $32.2 million.

Corvus Pharmaceuticals reported a net loss of $6.5 million for the second quarter of 2023, with cash, cash equivalents, and marketable securities totaling $37.0 million as of June 30, 2023. The company anticipates its cash will fund operations into the second half of 2024.

Corvus Pharmaceuticals reported a net loss of $7.9 million for the quarter ended March 31, 2023, compared to a net loss of $8.3 million for the same period in 2022. The company's cash, cash equivalents, and marketable securities totaled $34.5 million as of March 31, 2023. They expect full year 2023 net cash used in operating activities to be between approximately $19 million and $22 million.

Corvus Pharmaceuticals reported its Q4 and full year 2022 financial results, highlighting the progress of CPI-818 and its potential across cancer and immune diseases. The company's cash balance was $42.3 million as of December 31, 2022, and anticipates funding operations into 2024.

Corvus Pharmaceuticals reported its Q3 2022 financial results, with a net loss of $14.8 million. The company had $49.6 million in cash, cash equivalents, and marketable securities as of September 30, 2022, and anticipates several milestones for its clinical programs.

Corvus Pharmaceuticals reported a net loss of $8.4 million for the second quarter ended June 30, 2022, compared to a net loss of $11.8 million for the same period in 2021. As of June 30, 2022, Corvus had cash, cash equivalents and marketable securities totaling $56.7 million and expects its cash to fund operations into early 2024.

Corvus Pharmaceuticals reported a net loss of $8.3 million for the first quarter of 2022, compared to a net loss of $11.6 million for the same period in 2021. As of March 31, 2022, the company had cash, cash equivalents, and marketable securities totaling $62.9 million.

Corvus Pharmaceuticals reported a net loss of $9.2 million for the fourth quarter of 2021, with research and development expenses totaling $4.8 million. As of December 31, 2021, the company's cash, cash equivalents, and marketable securities amounted to $69.5 million.

Corvus Pharmaceuticals reported a net loss of $10.7 million for the third quarter ended September 30, 2021, compared to a net loss of $9.8 million for the same period in 2020. As of September 30, 2021, the company had cash, cash equivalents, and marketable securities totaling $76.3 million.

Corvus Pharmaceuticals reported a net loss of $11.8 million for the second quarter ended June 30, 2021. As of June 30, 2021, Corvus had cash, cash equivalents and marketable securities totaling $66.5 million.

Corvus Pharmaceuticals reported a net loss of $11.6 million for the first quarter ended March 31, 2021, and had cash, cash equivalents and marketable securities totaling $68.0 million as of the same date. The company is advancing its clinical programs, including a Phase 3 study of CPI-006 for COVID-19 and a Phase 2 study of CPI-818 for T cell lymphoma in partnership with Angel Pharmaceuticals.

Corvus Pharmaceuticals reported a net income of $27.1 million for the fourth quarter of 2020, with cash, cash equivalents, and marketable securities totaling $44.3 million as of December 31, 2020. The company is focused on advancing its clinical programs, including a Phase 3 study of CPI-006 for COVID-19.

Corvus Pharmaceuticals reported a net loss of $9.8 million for the third quarter ended September 30, 2020, and had cash, cash equivalents and marketable securities totaling $51.4 million at the end of the quarter.

Corvus Pharmaceuticals reported a net loss of $10.6 million for the second quarter of 2020, compared to a net loss of $13.0 million for the same period in 2019. The company's cash, cash equivalents, and marketable securities totaled $59.3 million as of June 30, 2020.

Corvus Pharmaceuticals reported a net loss of $12.9 million for the first quarter ended March 31, 2020, and had cash, cash equivalents and marketable securities totaling $68.7 million at March 31, 2020.

Corvus Pharmaceuticals reported a net loss of $11.0 million for the fourth quarter of 2019, with research and development expenses totaling $8.9 million. The company's cash, cash equivalents, and marketable securities amounted to $78.0 million as of December 31, 2019.